High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β2-adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts

Journal of Physiology

Volumn 595, Issue 6, 2017, Pages 1973-1986

  Fu, Qin ^a,b   Hu, Yuting ^a,b   Wang, Qingtong ^c,d   Liu, Yongming ^c,e   Li, Ning ^c   Xu, Bing ^c   Kim, Sungjin ^c   Chiamvimonvat, Nipavan ^c,f   Xiang, Yang K ^c,e,f  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ANHUI MEDICAL UNIVERSITY   (China)

^e SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^f VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

ardiac function; beta adrenergic receptor; high fat diet

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR KINASE; GLUCOSE; INSULIN; SERINE; ADRBK1 PROTEIN, MOUSE; G PROTEIN COUPLED RECEPTOR KINASE 2;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC MUSCLE CELL; CELL ISOLATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; FUNCTIONAL STATUS; GENE DELETION; GLUCOSE BLOOD LEVEL; HEART CONTRACTION; HEART DISEASE; HEART FUNCTION; HEART INNERVATION; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NERVE POTENTIAL; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; WEIGHT GAIN; ANIMAL; C57BL MOUSE; GENETICS; HEART; HYPERINSULINISM; KNOCKOUT MOUSE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIET, HIGH-FAT; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEART; HYPERINSULINISM; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; PHOSPHORYLATION; RECEPTORS, ADRENERGIC, BETA-2;

EID: 85011691071     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/JP273314     Document Type: Article

References (42)

1. Aneja A, Tang WH, Bansilal S, Garcia MJ & Farkouh ME (2008). Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121, 748–757.
2. Ansley DM & Wang B (2013). Oxidative stress and myocardial injury in the diabetic heart. J Pathol 229, 232–241.
3. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R & Joyner MJ (2007). Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293, E1289–E1295.
4. Bell DS (2003). Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26, 2433–2441.
5. Bernstein D, Fajardo G, Zhao M, Urashima T, Powers J, Berry G & Kobilka BK (2005). Differential cardioprotective/cardiotoxic effects mediated by β-adrenergic receptor subtypes. Am J Physiol Heart Circ Physiol 289, H2441–H2449.
6. Boudina S & Abel ED (2007). Diabetic cardiomyopathy revisited. Circulation 115, 3213–3223.
7. Brodde OE, Bruck H & Leineweber K (2006). Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 100, 323–337.
8. Brum PC, Rolim NP, Bacurau AV & Medeiros A (2006). Neurohumoral activation in heart failure: the role of adrenergic receptors. Anais da Academia Brasileira de Ciencias 78, 485–503.
9. Chuang TT, Iacovelli L, Sallese M & De Blasi A (1996). G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications. Trends Pharmacol Sci 17, 416–421.
10. 2-adrenergic receptor to different G proteins by protein kinase A. Nature 390, 88–91.
11. Daniels AM, van Bilsen BJ, Janssen AE, Brouns JP, Cleutjens TH, Roemen G, Schaart J, van der Velden GJ, van der Vusse FA & van Nieuwenhoven FA (2010). Impaired cardiac functional reserve in type 2 diabetic db/db mice is associated with metabolic, but not structural, remodelling. Acta Physiol (Oxf) 200, 11–22.
12. Desai A & Fang JC (2008). Heart failure with preserved ejection fraction: hypertension, diabetes, obesity/sleep apnea, and hypertrophic and infiltrative cardiomyopathy. Heart Failure Clinics 4, 87–97.
13. 3-adrenoreceptors in rat hearts. Diabetes 50, 455–461.
14. 2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 101, 71–77.
15. Fang ZY, Prins JB & Marwick TH (2004). Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25, 543–567.
16. Florea VG & Cohn JN (2014). The autonomic nervous system and heart failure. Circ Res 114, 1815–1826.
17. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ & Roger VL (2006). Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 119, 591–599.
18. 2-adrenergic signaling in hearts. Diabetes 63, 2676–2689.
19. 2AR internalization to attenuate βAR signaling in cardiomyocytes. Cell Signal 27, 707–715.
20. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ & Caron MG (2004). Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27, 107–144.
21. Grundy D (2015). Principles and standards for reporting animal experiments in The Journal of Physiology and Experimental Physiology. J Physiol 593, 2547–2549.
22. Haas SJ, Vos T, Gilbert RE & Krum H (2003). Are β-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146, 848–853.
23. Heyliger CE, Pierce GN, Singal PK, Beamish RE & Dhalla NS (1982). Cardiac alpha- and beta-adrenergic receptor alterations in diabetic cardiomyopathy. Basic Res Cardiol 77, 610–618.
24. Kubli DA & Gustafsson AB (2014). Cardiomyocyte health: adapting to metabolic changes through autophagy. Trends Endocrinol Metab 25, 156–164.
25. Liggett SB (2001). β-Adrenergic receptors in the failing heart: the good, the bad, and the unknown. J Clin Invest 107, 947–948.
26. Lymperopoulos A, Rengo G & Koch WJ (2013). Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 113, 739–753.
27. Mei Y, Thompson MD, Cohen RA & Tong X (2015). Autophagy and oxidative stress in cardiovascular diseases. Biochim Biophys Acta 1852, 243–251.
28. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A & Zimmerman RS (2012). Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 14, 803–809.
29. Qi Y, Xu Z, Zhu Q, Thomas C, Kumar R, Feng H, Dostal DE, White MF, Baker KM & Guo S (2013). Myocardial loss of IRS1 and IRS2 causes heart failure and is controlled by p38α MAPK during insulin resistance. Diabetes 62, 3887–3900.
30. Scognamiglio R, Avogaro A, Casara D, Crepaldi C, Marin M, Palisi M, Mingardi R, Erle G, Fasoli G & Dalla Volta S (1998). Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 31, 404–412.
31. Scognamiglio R, Fasoli G, Ferri M, Nistri S, Miorelli M, Egloff C, Buja G, Fedele D & Dalla-Volta S (1995). Myocardial dysfunction and abnormal left ventricular exercise response in autonomic diabetic patients. Clin Cardiol 18, 276–282.
32. Soto D, De Arcangelis V, Zhang J & Xiang Y (2009). Dynamic protein kinase A activities induced by β-adrenoceptors dictate signaling propagation for substrate phosphorylation and myocyte contraction. Circ Res 104, 770–779.
33. Tilley DG, Zhu W, Myers VD, Barr LA, Gao E, Li X, Song J, Carter RL, Makarewich CA, Yu D, Troupes CD, Grisanti LA, Coleman RC, Koch WJ, Houser SR, Cheung JY & Feldman AM (2014). β-Adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling. Circulation 130, 1800–1811.
34. Tillquist MN & Maddox TM (2012). Update on diabetic cardiomyopathy: inches forward, miles to go. Curr Diab Rep 12, 305–313.
35. Vadlamudi RV & McNeill JH (1984). Effect of experimental diabetes on isolated rat heart responsiveness to isoproterenol. Can J Physiol Pharmacol 62, 124–131.
36. Vasudevan NT, Mohan ML, Gupta MK, Martelli EE, Hussain AK, Qin Y, Chandrasekharan UM, Young D, Feldman AM, Sen S, Dorn GW, Dicorleto PE 2nd & Naga Prasad SV (2013). Gbetagamma-independent recruitment of G-protein coupled receptor kinase 2 drives tumor necrosis factor α-induced cardiac β-adrenergic receptor dysfunction. Circulation 128, 377–387.
37. Vinik AI & Ziegler D (2007). Diabetic cardiovascular autonomic neuropathy. Circulation 115, 387–397.
38. 2-adrenoceptor signaling is dictated by GRK2 phosphorylation in cardiomyocytes. J Biol Chem 283, 1799–1807.
39. Yu Z & McNeill JH (1991). Altered inotropic responses in diabetic cardiomyopathy and hypertensive-diabetic cardiomyopathy. J Pharmacol Exp Ther 257, 64–71.
40. Zhang X, Szeto C, Gao E, Tang M, Jin J, Fu Q, Makarewich C, Ai X, Li Y, Tang A, Wang J, Gao H, Wang F, Ge XJ, Kunapuli SP, Zhou L, Zeng C, Xiang KY & Chen X (2013). Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling. Circ Res 112, 498–509.
41. 2AR signaling links GRK2 upregulation to heart failure. Circ Res 110, 265–274.
42. 2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 98, 1607–1612.